出典: meddic


UpToDate Contents

全文を閲覧するには購読必要です。 To read the full text you will need to subscribe.


  • In vitro antifungal susceptibility profiles of Cryptococcus species isolated from HIV-associated cryptococcal meningitis patients in Zimbabwe.
  • Nyazika TK1, Herkert PF2, Hagen F3, Mateveke K4, Robertson VJ5, Meis JF6.
  • Diagnostic microbiology and infectious disease.Diagn Microbiol Infect Dis.2016 Nov;86(3):289-292. doi: 10.1016/j.diagmicrobio.2016.08.004. Epub 2016 Aug 8.
  • Cryptococcus neoformans is the leading cause of cryptococcosis in HIV-infected subjects worldwide. Treatment of cryptococcosis is based on amphotericin B, flucytosine, and fluconazole. In Zimbabwe, little is known about antifungal susceptibility of Cryptococcus. Sixty-eight genotyped Cryptococcus is
  • PMID 27608538
  • Molecular characterisation and antifungal susceptibility of clinical Cryptococcus deuterogattii (AFLP6/VGII) isolates from Southern Brazil.
  • Herkert PF1,2, Hagen F3, de Oliveira Salvador GL4, Gomes RR1,5, Ferreira MS6, Vicente VA1,7, Muro MD8, Pinheiro RL8, Meis JF2,9, Queiroz-Telles F10.
  • European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology.Eur J Clin Microbiol Infect Dis.2016 Nov;35(11):1803-1810. Epub 2016 Aug 1.
  • Cryptococcosis, caused by Cryptococcus gattii sensu lato, is an emerging disease that was initially found in (sub)tropical regions but recently expanded to temperate regions. Cryptococcus gattii s.l. infections are mostly encountered in healthy individuals, frequently affecting both lungs and the ce
  • PMID 27477855
  • Species diversity of Aspergillus section Versicolores in clinical samples and antifungal susceptibility.
  • Siqueira JP1, Sutton DA2, García D3, Gené J4, Thomson P3, Wiederhold N2, Guarro J3.
  • Fungal biology.Fungal Biol.2016 Nov;120(11):1458-1467. doi: 10.1016/j.funbio.2016.02.006.
  • Aspergillus section Versicolores includes species of clinical relevance and many others that have been poorly studied but are occasionally found in clinical samples. The aim of this study was to investigate, using a multilocus phylogenetic approach, the spectrum of species of the section Versicolore
  • PMID 27742099


  • 生物学的製剤を使用中に生じた皮膚クリプトコックス症の1例
  • 三宅 知美,福沢 正男,永松 清志郎 [他]
  • 日本皮膚科学会雑誌 122(7), 1765-1772, 2012-07
  • NAID 40019310427
  • Retrospective Analysis of Epidemiology and Prognostic Factors for Candidemia at a Hospital in China, 2000–2009
  • Zhang Xiao-Bing,Yu Shuang-Jiang,Yu Jun-Xiao,Gong Ya-Li,Feng Wei,Sun Feng-Jun
  • Japanese Journal of Infectious Diseases 65(6), 510-515, 2012
  • … Antifungal susceptibilities to fluconazole, flucytosine, and amphotericin B tended to decline over the study period. …
  • NAID 130002588759


2. 日本における発売年 1979(昭和54)年 3. 特長 経口投与で深在性真菌症の治療が可能である. 腎毒性がほとんど認められず,腎障害患者にも投与が可能である. 4. 承認済有効菌種 クリプトコックス カンジダ アスペルギルス
flucytosine /flu·cy·to·sine/ (floo-si´to-sēn″) an antifungal used in the treatment of severe candidal and cryptococcal infections. flucytosine [flo o sī′təsēn] an antifungal. indications It is prescribed as an adjunct in the treatment of certain ...






5-フルシトシン 5-flucytosine 5-FCアンコボン ancobon,5-フルオロシトシン 5-fluorocytosine